Since 2003, Lilly has worked hand in hand with its partners to prevent multidrug-resistant tuberculosis (MDR-TB) from gaining ground and taking more lives. Now funded by the Eli Lilly and Company Foundation, the Lilly MDR-TB Partnership brings together government leaders, global health organizations, country-level healthcare providers, community and advocacy organizations and other stakeholders to increase the availability of quality-assured medicine used to treat MDR-TB, enhance education for healthcare professionals where the need is greatest, and raise awareness of the disease amongst communities most at risk.
Global Health Advocates is a non-governmental organization that focuses on engaging all sections of society to fight diseases that disproportionately affect people living in poverty, and are also the leading causes of people living in poverty.
In particular, Global Health Advocates works towards the formulation and implementation of effective public policies to fight disease and ill health.
Established in 2001 as the Massive Effort Campaign, Global Health Advocates works in France and in India.
The Global Health Committee is focused on curing tuberculosis (TB) and effectively treating AIDS among the world's poorest populations. We believe that it is a fundamental human right to receive medicines for curable or treatable diseases.
Red Cross Red Crescent volunteers are involved at all levels in the fight against TB. Living in the affected communities they are best placed to:
Additionally, our volunteers provide social care after the first phase of treatment. Activities include:
These activities significantly increase the percentage of people who can be cured of TB.
National Red Cross Red Crescent Societies also communicate with national authorities, policy-makers and the public to ensure that the necessary resources are available to control TB.
The Lilly MDR-TB Partnership was created in 2003 to combat multidrug-resistant tuberculosis (MDR-TB). The International Hospital Federation has been a member of the project since 2004.
The IHF bilateral partnership was created in 2004 upon recognition of the need, firstly, to address TB management/treatment from the perspective of the hospital/healthcare setting.
Secondly, and even more importantly, upon acknowledgment that 'ignorance' and exclusion of IHF membership group, may have led and can lead to adoption and implementation of contra-productive decisions and actions in the fight against MDR-TB.
Despite recent progress, tuberculosis (TB) remains an important global public health problem. One-third of the world's population is currently infected with the tubercle bacillus that causes TB; and, according to the World Health Organization (WHO), there were 9.4 million new cases and 1.7 million deaths from TB in 2009.
Although TB is curable, inadequate TB control is one of the factors that has led to an increase in multidrug-resistant tuberculosis (MDR-TB), a particularly dangerous form of the disease, which is potentially incurable in many settings. MDR-TB is defined as disease caused by TB bacilli resistant to at least isoniazid and rifampicin, the two most powerful anti-TB drugs. Rates of MDR-TB are high in some countries and, coupled with the devastating effects of TB/HIV co-infection, threaten to undermine TB control efforts worldwide.
The Union has been a leader in tuberculosis prevention, control and treatment since it was founded in 1920 as the International Union Against Tuberculosis. It is mostly widely known for the research that led to the directly observed treatment, short course (DOTS) strategy, endorsed by the WHO and used to treat more than 37 million TB patients around the world.
The New Jersey Medical School Global Tuberculosis Institute at Rutgers, The State University of New Jersey is a force in the effort to conquer and cure tuberculosis worldwide. The Institute plays a leading role in the international arena, providing expertise in program development, education and training and research to ministers of health, national TB programs and healthcare providers around the globe.
The Institute's work has no borders. Battling TB on the front lines, it has a proven track record in building the political will and international cooperation needed to relegate this disease to the history books, where it belongs.
When RESULTS and REF began advocating for tuberculosis (TB) funding in 1997 as a key poverty and health issue, the U.S. was providing less than $1 million in global TB funding. Since then, we've helped members of Congress realize that not only is TB a global epidemic, but the fight against HIV/AIDS will not succeed without an equally aggressive effort against TB. In 2008, the historic Tom Lantos and Henry J. Hyde United States Global Leadership Against HIV/AIDS, Tuberculosis, and Malaria Reauthorization Act of 2008 was signed into law, authorizing $48 billion over five years for life-saving programs, including $4 billion for TB and a goal of treating 4.5 million people.
To reach this authorized level, Congress must begin to scale up TB funding as envisioned in this historic legislation. RESULTS continues to lead advocacy efforts to urge Congress to increase funding for the Global Fund in our annual appropriations (foreign aid spending) bill.
The Stop TB Partnership is leading the way to a world without tuberculosis (TB), a disease that is curable but still kills three people every minute. Founded in 2001, the Partnership's mission is to serve every person who is vulnerable to TB and ensure that high-quality treatment is available to all who need it.
Together our nearly 1000 partners are a collective force that is transforming the fight against TB in more than 100 countries. They include international and technical organizations, government programmes, research and funding agencies, foundations, NGOs, civil society and community groups and the private sector.
We operate through a secretariat hosted by the World Health Organization (WHO) in Geneva, Switzerland and seven working groups whose role is to accelerate progress on access to TB diagnosis and treatment; research and development for new TB diagnostics, drugs and vaccines; and tackling drug resistant- and HIV-associated TB. The secretariat is governed by a coordinating board that sets strategic direction for the global fight against TB.
TB Alert believes in a world without TB. It is possible. TB is curable, and early diagnosis and treatment helps to prevent the spread of TB. Unfortunately, it is not that simple. Whilst it is clinically possible to diagnose and treat most forms of the disease effectively, the people most vulnerable to TB – who tend to be the poorest and most marginalised in society – all too frequently fall through the gaps in service provision. As many as 40% of the 8.8 million people who develop the disease each year never reach a qualified doctor – those that do, frequently delay going to a doctor until the illness is advanced and therefore more difficult to treat. Even when people do receive a timely and accurate diagnosis, and are started on medication for TB, too many cease treatment before they have been successfully cured of the disease.
Working within national TB control programmes, TB Alert promotes a collaborative, social model of health to address TB. This model considers the social, cultural and economic factors that make some people more vulnerable to TB; less likely to seek help for possible TB symptoms; and less able to complete treatment successfully if diagnosed with the illness.
The mission of the Centres for Disease Control and Prevention Division of Tuberculosis Elimination (DTBE) is to promote health and quality of life by preventing, controlling, and eventually eliminating tuberculosis from the United States, and by collaborating with other countries and international partners in controlling global tuberculosis.
Health is one of the World Economic Forum's key focus areas as it is directly aligned with the Forum's mission: Committed to improving the state of the world by engaging leaders in shaping the global, regional and industry agendas. The Forum focuses on three key health-related activities: advocacy, dialogue and action through partnership.
The Forum recognises health as an important part of long-term economic development and engages its members and other stakeholders to advocate health as an investment.
The WHO Global TB Programme aims to advance universal access to TB prevention, care and control, guide the global response to threats, and promote innovation.
The World Medical Association (WMA) is an international organization representing physicians. It was founded on 17 September 1947, when physicians from 27 different countries met at the First General Assembly of the WMA in Paris. The organization was created to ensure the independence of physicians, and to work for the highest possible standards of ethical behaviour and care by physicians, at all times. This was particularly important to physicians after the Second World War, and therefore the WMA has always been an independent confederation of free professional associations. Funding has been by the annual contributions of its members, which has now grown to 100 National Medical Associations.
The WMA provides a forum for its member associations to communicate freely, to co-operate actively, to achieve consensus on high standards of medical ethics and professional competence, and to promote the professional freedom of physicians worldwide.
This unique partnership facilitates high-calibre, humane care to patients in a healthy environment, enhancing the quality of life for all people in the world.